Mastercard said it will acquire Ekata for $850 million in a deal that will bolster its identity verification technology. Ekata's application programming interfaces (APIs) and tools are used by merchants, marketplaces and financial firms across multiple industries. Ekata's platform provides artificial intelligence enhanced risk scoring, indicators and data attributes. The purchase of Ekata will also bolster Mastercard's digital identity and security framework. Ekata offers a bevy of identify verification services to prevent fraud.
Enterprise analytics company Clarify Health has secured $115 million in series C funding to scale its self-service healthcare analytics cloud and business software. Clarify Health combines longitudinal data for more than 300 million "unique patient lives" from government and commercial claims, electronic health records (EHRs) and prescriptions, according to the company. These data can help healthcare professionals manage population health and commercialize pharmaceutical and biotechnology products. "By linking CMS claims data with commercial claims, EHR, prescription and socioeconomic data, our models are trained on large cohorts and a more complete picture of each patient's longitudinal healthcare journey," Clarify Health CEO Jean Drouin, M.D., told Fierce Healthcare. The San Francisco-based company was launched in 2015 and has raised $178 million to date, according to Crunchbase.
Forecasts by Application (Drug Discovery, Precision Medicine, Medical Imaging & Diagnostics, Research), by Technology (Machine Learning, Other Technologies), by Offering (Hardware, Software, Services), by Deployment (Cloud, On-Premises) AND Regional and Leading National Market Analysis PLUS Analysis of Leading AI Companies AND COVID-19 Recovery ScenariosNew York, April 15, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Artificial Intelligence (AI) in Pharmaceutical Market Report 2021-2031" - https://www.reportlinker.com/p06061831/?utm_source=GNW How Adoption of Artificial Intelligence Impacting Pharmaceutical Industry? The global pharmaceuticals industry is in the throes of transition, both clinical trials and regulatory approvals have been challenged by the proliferation of specialized drugs catering to smaller patient groups. In order to boost results in drug discovery, clinical trials, and research and development, the pharmaceutical and life sciences companies are switching to robotic process control, artificial intelligence and machine learning. All these factors are anticipated to propel demand for artificial intelligence in pharmaceutical across the globe. Artificial Intelligence Anticipated to Revolutionize Several Aspects of Pharmaceutical Industry The way drugs are made, prescribed and ingested today will be standardized by artificial intelligence. Many facets of the pharmaceuticals and life sciences industry will also be revolutionized but will not heal sickness or replace physicians. Understanding the main aim of artificial intelligence, which is to improve human capability and accomplishment instead of challenging it, would dispel much of the technology’s concerns and put out its excellent ability to serve humanity. Which Factors are Fueling AI in Pharmaceuticals Industry Growth? . Growing Complexity of Modern Pharmacology . Growing Demand for Viable Therapeutic Candidates . Improves Overall R&D Productivity . Concerns Associated with Rising Capital Requirements in Drug Discovery . Increasing Awareness Related to Artificial Intelligence Among Pharmaceutical Manufacturers Which Factors are Restraining Growth? . Lack of Skilled Professionals . Limited Availability of Datasets UNIQUE COVID-19 VARIATIONS- only available in this Visiongain report are dedicated analysis of 4 different rebound scenarios of how the market will develop - no matter how COVID-19 affects the economy. To access the data contained in this document please email email@example.com How do prominent players strengthen their position throughout the world? You must read this newly updated report if you are involved in this sector. The report from Visiongain shows you potential revenues up to 2031, evaluate information, trends, opportunities and business outlooks. Discover how to stay ahead Our 350+ page report provides 500+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing AI in Pharmaceuticals Market. See how to exploit the opportunities. Forecasts to 2031 and other analyses reveal the commercial prospects . In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares. . You find original analyses, with business outlooks and developments. . Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), SWOT Analysis, PEST Analysis, Porter’s Analysis, product profiles and commercial developments. Discover sales predictions for the world market and submarkets Application . Drug Discovery . Precision Medicine . Medical Imaging & Diagnostics . Research Technology . Machine Learning . Other Technologies Offering . Hardware . Software . Services Deployment . Cloud . On-Premises In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 13 leading national markets: By Region (Segmental Breakdown for All the Regions) . North America - U.S. - Canada . Europe - Germany - France - UK - Italy - Spain - Rest of Europe . Asia Pacific - China - Japan - India - Rest of Asia Pacific . RoW Need industry data? Please contact us today. Leading companies and the potential for market growth Overall world revenue for AI in Pharmaceuticals Market will surpass $xx billion in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead. Prospects for established firms and those seeking to enter the market- including company profiles for 16 of the major companies involved in the AI in Pharmaceuticals Market. Some of the companies profiled in this report include are Microsoft Corporation, NVIDIA Corporation, IBM Corporation, Alphabet Inc., Atomwise, Inc., Deep Genomics, Cloud Pharmaceuticals, Inc., Insilico Medicine, BenevolentAI, Exscientia, Biosymetrics, Euretos, Insitro, Cyclica, Biovista, and OWKIN, INC. Key Questions Answered by this Report . What is the current size of the overall global AI in Pharmaceuticals market? How much will this market be worth from 2021 to 2031? . What are the main drivers and restraints that will shape the overall AI in Pharmaceuticals market over the next ten years? . What are the main segments within the overall AI in Pharmaceuticals market? How much will each of these segments be worth for the period 2021 to 2031? How will the composition of the market change during that time, and why? . What factors will affect that industry and market over the next ten years? . What are the largest national markets for the world AI in Pharmaceuticals? What is their current status and how will they develop over the next ten years? What are their revenue potentials to 2031? . How will market shares of the leading national markets change by 2031, and which geographical region will lead the market in 2031? . Which are the leading companies and what are their activities, results, developments, and prospects? . What are the main trends that will affect the world AI in Pharmaceuticals market between 2021 and 2031? . What are the main strengths, weaknesses, opportunities, and threats for the market? . How will the global AI in Pharmaceuticals market evolve over the forecasted period, 2021 to 2031? . How will market shares of prominent national markets change from 2021, and which countries will lead the market in 2031, achieving highest revenues and fastest growth? Read the full report: https://www.reportlinker.com/p06061831/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
Here's a look at how the cloud leaders stack up, the hybrid market, and the SaaS players that run your company as well as their latest strategic moves. IBM said it will acquire process mining company myInvenio as it aims to automate more business processes. Terms of the deal weren't disclosed. IBM and myInvenio, based in Reggio Emilia, Italy, launched a partnership in November. According to IBM, myInvenio can use its platform to find the best business processes to automate with AI.
Swag has a long and patchy history in the world of business. For every hip pair of plaid socks, there are five t-shirts you may never wear, an itchy scarf, a notepad your kids might use, and an ugly mug; and most of all, likely thousands of dollars and lots of time invested to make those presents a reality. Now, a startup that has built a service to rethink the concept behind corporate gifts and make them more effective is today announcing a round of funding to continue expanding its business -- and one sign that it may be on to something is its progress so far. Alyce, a Boston startup that has built an AI platform that plugs into various other apps that you might use to interact and track your relationships with others in your working life -- sales prospects, business partners, colleagues -- and then uses the information to personalise gift recommendations for those people, has raised $30 million, a Series B that it will be using to continue building out its platform, signing up more users, and hiring more people for its team. This round is being led by General Catalyst, with Boston Seed Capital, Golden Ventures, Manifest, Morningside and Victress Captial -- all previous backers -- also participating.
Graphics-chip maker Nvidia (NVDA) released a fire hose of news at its online GTC conference, detailing advancements in artificial intelligence, computer graphics, robotics and data centers. Nvidia stock reached a buy point Tuesday following positive reviews of the event. Nvidia also announced that its fiscal first-quarter revenue is tracking above the target it provided in its Feb. 24 earnings release. At the time, the company provided a revenue outlook for its first fiscal quarter, ending May 2, of $5.3 billion, plus or minus 2%. In a news release, Chief Financial Officer Colette Kress said Nvidia is seeing strength across its four market platforms.
Government regulations and new privacy rules instituted by Apple Inc. and Alphabet Inc.'s Google will limit the ability of advertisers, publishers and tech companies to track users and target ads based on identifiable data. Going forward, marketers will have to revamp their data strategies, while adtech vendors and other companies are hurrying to find alternative ways to reach consumers. One such alternative is contextual advertising: targeting ads by placing them close to relevant content. GumGum uses computer-vision and natural-language processing technologies to scan and analyze text, images, video and audio to help match ads to content. CMO Today delivers the most important news of the day for media and marketing professionals.
Register for a free or VIP pass today. CrowdAI, a computer vision development platform, today announced that it closed a $6.25 million series A financing round led by Threshold Ventures. The fundraising coincides with the launch of the startup's new solution that allows customers to create AI that analyzes images and videos. The AI skills gap remains a significant impediment to adoption in most enterprises, a 2020 O'Reilly survey found. Slightly more than one-sixth of respondents cited difficulty in hiring experts as a barrier to AI deployment in their organizations.
Register for free or grab a discounted VIP pass today. Tax compliance platform Blue Dot (previously VatBox) today announced it has raised $32 million, bringing its total raised to over $96 million. The firm says it will put the funds toward product R&D and expanding the size of its globlal workforce. The tax compliance burden for enterprises can be significant. In 2019, half of companies responding to an EY Americas survey indicated that their biggest compliance challenge would be staying current on legislative and regulatory developments.
AI models not only take time to build and train, but also to deploy in an organization's workflow. That's where MLOps (machine learning operations) companies come in, helping clients scale their AI technology. InfuseAI, a MLOps startup based in Taiwan, announced today it has raised a $4.3 million Series A, led by original design manufacturer Wistron Corporation, with participation from Hive Ventures, Top Taiwan Venture Capital Group and Silicon Valley Taiwan Investments. Founded in 2018, InfuseAI says the market for MLOps solutions is worth $30 million a year in Taiwan, with the global market expected to reach about $4 billion by 2025, according to research firm Cognilytica. Its clients include E.SUN, one of Taiwan's largest banks, SinoPac Holdings and Chimei. InfuseAI helps companies deploy and manage machine learning models with turnkey solutions like PrimeHub, a platform that includes a model training environment, cloud or on-premise cluster computing (including container orchestration with Kubernetes) and collaboration tools for teams.